Zevra Therapeutics (NASDAQ:ZVRA) Hits New 52-Week High – Should You Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $14.75 and last traded at $14.7450, with a volume of 102392 shares traded. The stock had previously closed at $14.44.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ZVRA shares. Canaccord Genuity Group upped their price objective on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Citizens Jmp upped their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 9th. Maxim Group increased their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Finally, Guggenheim boosted their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Stock Performance

The firm’s 50 day moving average price is $11.85 and its two-hundred day moving average price is $10.10. The firm has a market cap of $845.36 million, a PE ratio of 7.20 and a beta of 0.85.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, analysts forecast that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in Zevra Therapeutics in the fourth quarter valued at about $53,000. Russell Investments Group Ltd. raised its stake in shares of Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares during the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $92,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Zevra Therapeutics during the 2nd quarter worth approximately $99,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.